Krystal Biotech (KRYS) Non Operating Income (2017 - 2019)

Krystal Biotech has reported Non Operating Income for 7 years, with the latest figure at $7.7 million in Q2 2026.

• Non Operating Income for Q2 2026 came in at $7.7 million, up 3.88% year-over-year; the trailing twelve-month figure through Jun 2026 was $28.9 million (down 1.31% YoY), and the FY2025 annual result was $28.2 million, down 4.84% from the prior year.
• Non Operating Income declined to $7.7 million in Q2 2026, from $7.8 million in the prior quarter.
• Over five years, Non Operating Income peaked at $7.8 million in Q1 2026 and troughed at $6.6 million in Q3 2025.
• A 4-year average of $7.3 million and a median of $7.4 million in 2025 frame the typical range for Non Operating Income.
• The widest annual swing landed in 2024, when Non Operating Income rose 8.26%; it then declined 9.65% in 2025.
• A 4-year view of Non Operating Income shows it stood at $7.4 million in 2023, then slipped by 2.35% to $7.2 million in 2024, then dropped by 5.17% to $6.9 million in 2025, then grew by 11.67% to $7.7 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $7.7 million in Q2 2026, $7.8 million in Q1 2026, and $6.9 million in Q4 2025.